Tofacitinib and pirfenidone as rescue therapies for severe COVID ‐19 in a patient with previously stable interstitial lung disease associated with Sjögren syndrome
International Journal of Rheumatic Diseases · 2024
DOI: 10.1111/1756-185x.14890 ↗Kurz gefasst
Fallbericht in der Zeitschrift International Journal of Rheumatic Diseases, 2024. Verfasst von Yu-Chuan Tsao und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Taichung Armed Forces General Hospital, Taichung, Taiwan. Hauptthemen laut MEDLINE: COVID-19, Sjogren's Syndrome, Lung Diseases, Interstitial, Idiopathic Pulmonary Fibrosis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 17 Literaturangaben.
Abstract (Originalsprache)
Coronavirus disease 2019 (COVID‐19) can lead to pulmonary fibrosis due to the inflammatory process in the lung, resulting in a series of respiratory consequences. Patients with underlying systemic diseases or pre‐existing pulmonary diseases are particularly at risk of severe respiratory distress and persistent pulmonary abnormalities. Pirfenidone, a well‐known anti‐fibrotic agent recognized for its therapeutic effect on idiopathic pulmonary fibrosis, could be a feasible option in severe COVID‐19 cases given the similar pathophysiological features shared with interstitial lung diseases. In this paper, we share our experience of early administration of pirfenidone in combination with tofacitinib in a 61‐year‐old female patient with severe COVID‐19 pneumonia. Pirfenidone was initiated because of persistent dependence on high‐flow oxygen support and even the requirement for mechanical ventilation due to disease progression after initial standard COVID‐19 treatment. The patient was successfully extubated 15 days after the initiation of pirfenidone, and 13 days after extubation, she was completely weaned off supplemental oxygen. A series of chest radiographs and computed tomography scans demonstrated notable improvements in her lung condition. We propose a strategy of using pirfenidone plus tofacitinib as a rescue therapy in the management of patients with severe COVID‐19.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Taichung Armed Forces General Hospital, Taichung, Taiwan.
- Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
- Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
- Department of Public Health, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
ORCID-Profile: Chih-Wei Tseng
Zitieren
APA
Tsao, Y. C., Chuang, S. H., & Tseng, C. W. (2024). Tofacitinib and pirfenidone as rescue therapies for severe COVID ‐19 in a patient with previously stable interstitial lung disease associated with Sjögren syndrome. International Journal of Rheumatic Diseases. https://doi.org/10.1111/1756-185x.14890
Vancouver
Tsao YC, Chuang SH, Tseng CW. Tofacitinib and pirfenidone as rescue therapies for severe COVID ‐19 in a patient with previously stable interstitial lung disease associated with Sjögren syndrome. International Journal of Rheumatic Diseases. 2024. doi:10.1111/1756-185x.14890
BibTeX
@article{Tsao2024,
author = {Tsao, Yu-Chuan and Chuang, Shih-Han and Tseng, Chih-Wei},
title = {Tofacitinib and pirfenidone as rescue therapies for severe COVID ‐19 in a patient with previously stable interstitial lung disease associated with Sjögren syndrome},
journal = {International Journal of Rheumatic Diseases},
year = {2024},
doi = {10.1111/1756-185x.14890}
}
EUVIMED